The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Kurbatova I.V.

Moskovskiĭ nauchno-prakticheskiĭ Tsentr dermatovenerologii i kosmetologii Departamenta zdravookhraneniia Moskvy, Moskva, Rossiia, 119071

Dudanova O.P.

Petrozavodsk State University, Petrozavodsk, Russia

Features of a necrotic and inflammatory process in different forms of nonalcoholic fatty liver disease

Authors:

Kurbatova I.V., Dudanova O.P.

More about the authors

Journal: Therapeutic Archive. 2017;89(2): 52‑58

Read: 2872 times


To cite this article:

Kurbatova IV, Dudanova OP. Features of a necrotic and inflammatory process in different forms of nonalcoholic fatty liver disease. Therapeutic Archive. 2017;89(2):52‑58. (In Russ.)
https://doi.org/10.17116/terarkh201789252-58

Recommended articles:
Morphogenesis and mole­cular regu­lation of poly­posis rhinosinusitis. Russian Journal of Archive of Pathology. 2025;(1):68-76
The level of hypo­xia-induced factor-1a and asso­ciated mole­cules in preeclampsia. Russian Bulletin of Obstetrician-Gynecologist. 2025;(1):5-10
Clinical and immu­nological rela­tionships in patients with early schi­zophrenia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):35-42
Cyto­kine status of patients with Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):5-12
The condition of bone tissue in patients with non-alcoholic fatty liver disease. Russian Journal of Preventive Medi­cine. 2025;(5):82-89

References:

  1. Stefan N, Kantartzis K, Häring HU. Causes and metabolic consequences of Fatty liver. Endocrine Reviews. 2008;29(7):939-960. doi:10.1210/er.2008-0009
  2. Drapkina OM, Deeva TA, Volkova NP, Ivashkin VT. Current approaches to diagnosing and treating nonalcoholic fatty liver disease. Terapevticheskij arkhiv. 2014;86(10):116-123. (In Russ.).
  3. Bespalova ID, Ryazantseva NV, Kalyuzhin VV, Afanasyeva DS, Myrashev BYu, Osikhov IA. Systemic inflammation in pathogenesis of metabolic syndrome and associated diseases. Sibirskij medicinskij zhurnal. 2013;(2):5-9. (In Russ.).
  4. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World Journal of Gastroenterology. 2012;18(8):727-735. doi:10.3748/wjg.v18.i8.727
  5. Stilidi EI. The role of tumor necrosis factor alpha and interleukin-6 in the pathogenesis of NASH. Krymskij terapevticheskij zhurnal. 2012;(1):91-98. (In Russ.).
  6. Guicciardi ME, Gores GJ. Apoptosis as a mechanism for liver disease progression. Seminars in Liver Disease. 2010;30(4):402-410. doi:10.1055/s-0030-1267540
  7. Copaci I, Micu L, Voiculescu M. The role of cytokines in non-alcoholic steatohepatitis. A review. Journal of Gastrointestinal and Liver Diseases. 2006;15(4):363-373.
  8. Pаr A, Pаr G. Liver fibrosis: patho-physiology, diagnosis and treatment. Orvosi Hetilap. 2005;146(1):3-13.
  9. Zvyagintseva TD, Glushchenko SV. Lipotoxic stress and proinflammatory cytokines as factors in the development of nonalcoholic steatohepatitis. Nauchnye vedomosti. Serija Medicina. Farmacija. 2014;18(189):46-49. (In Russ.).
  10. Sivkova AA, Lareva NV, Luzina EV. Pathogenetic significance of cytokines in the formation and development of non alcoholic fatty liver disease (NAFDL). Sibirskij medicinskij zhurnal. 2011;(4):56-58. (In Russ.).
  11. Brunt EM., Janney CG., Di isceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. The American Journal of Gastroenterology. 1999;94(9):2467-2474. doi:10.1016/s0002-9270(99)00433-5
  12. Bozec A, Ruffion A, Decaussin M, Andre J, Devonec M, Benahmed M, Mauduit C. Activation of caspases-3, -6, and -9 during finasteride treatment of benign prostatic hyperplasia. Journal of Clinical Endocrinology & Metabolism. 2005;90(1):17-25. doi:10.1210/jc.2004-0712
  13. Mrass P, Rendl M, Mildner M, Gruber F, Lengauer B, Ballaun C, Eckhart L, Tschachler E. Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids. Cancer Research. 2004;64(18):6542-6548. doi:10.1158/0008-5472.can-04-1129
  14. Livak KJ., Schmittgen TD. Analysis of relative gene expression data using Real-Time quantitative PCR and the 2—∆∆CT method. Methods. 2001;25(4):402-408. doi:10.1006/meth.2001.1262
  15. Papa S, Bubici C, Zazzeroni F, Franzoso G. Mechanisms of liver disease: cross-talk between the NF-kappaB and JNK pathways. Biological Chemistry. 2009;390(10):965-976. doi:10.1515/bc.2009.111
  16. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. Journal of Clinical Investigation. 1995;95(5):2409-2415. doi:10.1172/jci117936
  17. Lesmana CR, Hasan I, Budihusodo U, Gani RA, Krisnuhoni E, Akbar N, Lesmana LA. Diagnostic value of a group of biochemical markers of liver fibrosis in patients with non-alcoholic steatohepatitis. Journal of Digestive Diseases. 2009;10(3):201-206. doi:10.1111/j.1751-2980.2009.00386.x
  18. Zahran WE, Salah El-Dien KA, Kamel PG, El-Sawaby AS. Efficacy of Tumor Necrosis Factor and Interleukin-10 Analysis in the Follow-up of Nonalcoholic Fatty Liver Disease Progression. Indian Journal of Clinical Biochemistry. 2012;28(2):141-146. doi:10.1007/s12291-012-0236-5
  19. Tsukamoto H. Is interleukin-10 antifibrogenic in chronic liver injury? Hepatology. 1998;28(6):1707-1709. doi:10.1002/hep.510280635
  20. Yilmaz Y. Systematic review: caspasecleaved fragments of cytokeratin 18 (the promises and challenges of a biomarker for chronic liver disease. Alimentary Pharmacology & Therapeutics. 2009;30(11-12):1103-1109. doi:10.1111/j.1365-2036.2009.04148.x
  21. Ribeiro PS, Cortez-Pinto H, Solá S, Castro RE, Ramalho RM, Baptista A, Moura MC, Camilo ME, Rodrigues CM. Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. The American Journal of Gastroenterology. 2004;99(9):1708-1717. doi:10.1111/j.1572-0241.2004.40009.x
  22. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. Journal of Clinical Investigation. 2004;(114):147-152. doi:10.1172/jci200422422
  23. Negrin KA, Roth Flach RJ, DiStefano MT, Matevossian A, Friedline RH, Jung D, Kim JK, Czech MP. IL-1 signaling in obesity-induced hepatic lipogenesis and steatosis. PLoS One. 2014;9(9):e107265. doi:10.1371/journal.pone.0107265

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.